Patents Assigned to LBL Biotechnology Inc.
  • Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor
    Patent number: 11661450
    Abstract: Methods and compositions relating to combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor are provided.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: May 30, 2023
    Assignee: LBL Biotechnology Inc.
    Inventor: Ming-Shi Chang
  • Use of IL-20 antagonists for treating eye diseases
    Patent number: 11279755
    Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 22, 2022
    Assignee: LBL Biotechnology, Inc.
    Inventor: Ming-Shi Chang
  • COMBINATION THERAPY USING AN IL-20 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20210332121
    Abstract: Methods and compositions relating to combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor are provided.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 28, 2021
    Applicant: LBL Biotechnology Inc.
    Inventor: Ming-Shi CHANG